FineHeart Announces Success of the First Stage of Its "First in Human" Clinical Study
The results were presented at the 8th EACTS summit European Association for Cardiac and Thoracic Surgery
FineHeart, a clinical-stage MedTech company developing innovative medical devices for heart failure, has achieved a major milestone in its "First in Human" study, clinically confirming the proof of concept for FlowMaker
The device was implanted in patients with advanced heart failure for the first time on a beating heart, without an intensive cardiac arrest procedure, thereby reducing surgical risks and improving the patients' recovery. The procedure was performed using a new minimally invasive technique, allowing FlowMaker to synchronize its operation with the natural contractions of the heart, and optimize blood flow without requiring an external bypass, unlike all other devices.
Due to its compact size and low energy consumption, the fully implanted FlowMaker benefits from wireless power supply, which represents a significant and unparalleled progress for patients awaiting long-term hemodynamic support.
These implantations are part of a "First in Human" European study conducted by Professor Ivan Netuka, MD, Principal Investigator, Head of the Department of Cardiovascular Surgery, and his team at the IKEM (Prague), a center of excellence for cardiovascular research.
The first results were presented by Professor Netuka during a plenary session specifically dedicated to clinical studies on Friday, November 8, 2024, at the 8th International Summit on Mechanical Circulatory Support organized by EACTS, the European Association for Cardiac and Thoracic Surgery.
The FineHeart Research and Development team would like to offer their sincere thanks to Professor Ivan Netuka for his leadership and vital contribution throughout this project: "This success is the result of a close collaboration and the commitment of both teams"
Arnaud Mascarell, CEO and co-founder of FineHeart, underlines the importance of this milestone for the company's development: "This crucial achievement allows us to realize FineHeart's vision. The results observed provide promising insights into what we can offer patients with advanced heart failure and pave the way for international multicenter trials aimed at confirming these results on patients over longer periods."
Dr. Stéphane Garrigue, MD, PhD, CSO and co-founder of FineHeart, adds: "The results observed in particularly vulnerable patients confirm the potential that FineHeart had already identified in numerous preclinical studies. This first stage of the 'First in Human' study marks a significant step towards effective wireless therapy that is more physiological, less invasive, and better adapted than existing treatments."
Professor Laurent Barandon, MD, PhD, cardiac surgeon in Bordeaux and surgical team trainer for FlowMakerimplantation, concludes: "The surgical tools developed by FineHeart for this pilot study were successfully implemented by the Prague team, demonstrating the feasibility of this new minimally invasive operative procedure. The capacity of this fully implantable wireless medical device to support the natural cardiac function could expand therapeutic options for many patients with less severe forms of the disease."
About FLOWMAKER is the first implantable cardiac output accelerator, designed by French electrophysiologists and rhythmologists. Fully intraventricular, it provides physiological support synchronized with the natural heart contractions. It respects natural blood flow and does not require aortic bypass, unlike other devices. It is the first miniaturized device only 10 cm that adapts to patients' needs like a pacemaker, allowing targeted treatment based on the severity and progression of the disease. Completely implanted in the patient's body, it has no external power cables as it is recharged via a transcutaneous energy transfer (TET) system, thereby avoiding any risk of infection and significantly improving patients' quality of life. The device is implanted through a minimally invasive procedure on a beating heart, with an average duration of 90 minutes. Thanks to its unique features, FLOWMAKER represents an effective and highly promising therapeutic alternative for over 200,000 patients per year suffering from severe heart failure who cannot benefit from current therapeutic solutions.
About IKEM IKEM Institute of Clinical and Experimental Medicine IKEM.
About FineHeart FineHeart
View source version on businesswire.com: https://www.businesswire.com/news/home/20241113755422/en/
Contacts:
Media Relations
Annie-Florence Loyer
afloyer@newcap.fr
+33 (0) 6 88 20 35 59
FineHeart Communications
James Palmer
j.palmer@orpheonfinance.com
+33 (0) 7 60 92 77 72
